Biolase (BIOLQ) 8-K JMP Securities Healthcare Conference

BIOLASE Technology, Inc.

Federico Pignatelli, CEO

NASDAQ: BLTI

www.biolase.com

JMP Securities Healthcare Conference

September 27-28, 2011, New York

Exhibit 99.1

Safe Harbor Statement

PAGE

2

This presentation may contain forward-looking statements that are based on our current expectations, estimates

and projections about our industry as well as management’s beliefs and assumptions. Words such as “anticipates,”

“expects,” “intends,” “plans,”  “believes,”  “seeks,” “estimates,” “may,” “will,” and variations of these words or similar

expressions are intended to identify forward-looking statements. These statements include projections about our

future earnings and margins and speak only as of the date hereof. Such statements are based upon the

information available to us now and are subject to change. We will not necessarily inform you of such changes.

These statements are not guarantees of future performance and are subject to certain risks, uncertainties and

assumptions that are difficult to predict. Therefore our actual results could differ materially and adversely from

those expressed in any forward-looking statements as a result of various factors. The important factors which

could cause actual results to differ materially from those in the forward-looking statements include, among others,

a downturn or leveling off of demand for our products due to the availability and pricing of competing products and

technologies, adverse international market or political conditions, a domestic economic recession, the volume and

pricing of product sales, our ability to control costs, intellectual property disputes, the effects of natural disasters

and other events beyond our control and other factors including those detailed in BIOLASE’s filings with the

Securities and Exchange Commission including its prior filings on Form 10-K and 10-Q.

BIOLASE is revolutionizing surgery by breaking the limitations of conventional dentistry and

medicine.

PAGE 3

New management is transforming BIOLASE from a one product, one segment company of the past to a

multi-product

and

multi-segment

platform

company

that

will

be

better

diversified

in

2012

and

beyond

and

better

positioned

for

substantial

growth

compared

to

the

“old”

BIOLASE.

In

2011,

BIOLASE

has

better

positioned itself

product-wise

due

to

the

release

of

its

revolutionary

all-tissue

WaterLase

iPlus,

which

now

equals

the

speed

of

a

dental

drill;

the

iLase,

the

first

battery

operated

handheld

diode

laser;

and

the

introduction

of

a

full

line

of

digital

imaging

devices.

BIOLASE

is

expecting

to

launch

several

new

and

cutting

edge laser products in 2012.

BIOLASE is NOT Just Another Medical

Equipment Company!

Traditional Dentistry

The painting Cavadenti, the Tooth Puller, by Caravaggio, circa 1608

PAGE 4

Years of engineering and research at BIOLASE led to the discovery that the Er,Cr:YSGG (2796nm) laser

crystal (Erbium, Chromium doped Yttrium-Scandium-Gallium-Garnet) has the highest level of absorption

in water molecules contained in human tissue.  This absorption creates an expansion and vaporization

of the water molecules causing a biological ablation of human tissue including teeth, dentin, bone, gum,

skin and the eye).  For example, tooth enamel contains up to 5% water, dentin and bone contain up to 25% water,

soft tissue (gum tissue and skin) contains up to 80% water, and the eye contains up to 90% water. 

PAGE 5

Conventional Surgical Devices include the scalpel, high speed drill,

electrosurge, electric bone saws, and heat generating lasers.

How has BIOLASE Revolutionized Surgery?

…through the science of WaterLase!

Why BIOLASE WaterLase Technology in Dentistry?

Traditional

high-speed

drills

work

by

FRICTION

which

creates

HEAT

which

causes

PAIN.

This

PAIN

necessitates

injections

of

ANESTHESIA

which

results

in

PAIN

and

NUMB

LIPS.

In

addition, the lack of feeling from the numbing injections can lead to THERMAL DAMAGE

which can lead to PULPAL DEATH and result in a ROOT CANAL.

The

traditional

high-speed

drill

also

causes

VIBRATION,

which

causes

PAIN

and

leads

to

MICROFRACTURES.  These MICROFRACTURES allow BACTERIA to penetrate the tooth

which causes further DECAY and the FRACTURING of teeth.

High

speed

drills

also

require

the

use

of

BURS

which

even

after

autoclaving

have a 15% chance of carrying pathogenic micro-organisms.  Needles

and files can also carry bacteria.  That means in traditional dentistry the

patient has a 1 in 6 chance of cross contamination.

WaterLase energy

does not create heat or vibration so there is NO PAIN.  Further, the

WaterLase is bactericidal, antiviral and essentially eliminates the risk of cross contamination.

PAGE 6

Alternative

and

Advanced

Hi-Tech

Dentistry

Atraumatic Pediatric Tooth Extraction

The aiming beam on

the NEW WaterLase 

iPlus is green.  This

red beam featured in

the previous

generation of

WaterLase products

does not cut the

tissue.  Tissue is cut

biologically, with

water at the

molecular level.

Using BIOLASE WaterLase Systems, including our new WaterLase iPlus System:

PAGE 7

The iPlus features an

intuitive, touch-based

computer screen,

similar to a tablet

personal computer. 

It is designed to

allow for remote

servicing and

software upgrades.

WaterLase High Speed Cutting

PAGE 8

WaterLase vs. Drill     

PAGE 9

Alternative

Dentistry

is

Less

Frightening

•

There

are

160,000

dentists

currently

serving

a

population

of

300

million

Americans which means that 75 million Americans are avoiding dental care

because

of

fear.

This

equates

to

an

average

of

470

patients

per

dentist!

•

Patients spend about $1,000 per year on dental care, meaning that U.S.

dentists are missing out on an average of $470,000 of potential revenue,

every year.  If a dentist that adopts painless WaterLase Technology realizes

only half of this potential, they could earn an additional $235,000 in annual

revenue by just

serving fearful patients. 

PAGE 10

Using

the

dental

drill

offers

more

of

the

same

which

is

pain,

local

anesthetic,

swelling,

pain

killers,

micro-

fractures

and

cross

contamination.

WaterLase

technology

offers

a

biological

solution

with

none

of

the

downsides  

of traditional dentistry: NO drill, NO shot, NO pain, and NO cross contamination of bacteria or viruses.

According to the ADA, nearly 25% of all Americans avoid

dentists because they are afraid of dental drills and needles. 

WaterLase’s Amazing Return on Investment

•

WaterLase technology enables traditional dentists to perform procedures that they

currently refer out to specialists or WaterLase dentists, for example:

•

Gingivectomy = $160

•

Perio Treatment = $375

•

Hard-tissue Crown Lengthening = $520

•

Herpetic or Aphthous Ulcer = $308

•

Frenectomy = $355

•

This equates to $250-$750 per day in additional revenue

•

These procedures are easy to learn and training is included in the cost of the

WaterLase.

Monthly Lease Payment

New Monthly Revenue Generated

Approx. $1,000

$5,000 –

$15,000

PAGE 11

A dentists’

return on

investment can be

between 500%       

and 1,500%!

Substantial Data:

•

The effectiveness of dental   

lasers is proven and well   

researched.

•

Clinical data and peer-

reviewed specialty journals   

substantiate the effectiveness of

laser treatment in a wide variety

of procedures.

Technology Supported by Scientific Data

PAGE 12

Some of the Dental Schools that are Teaching

WaterLase Technology around the World   

PAGE 13

1. Dental Health Magazine 2. Dental Burs and Endodontic Files: Are Routine Sterilization Procedures Effective?: Archie

Morrison, DDS, MS, FRCD(C); Susan Conrod, DDS JCDA •

www.cda-adc.ca/jcda •

February 2009, Vol. 75, No. 1.  3.

Contaminated dental instruments: Smith A, Dickson M, Aitken J, Bagg J.J Hosp Infect. 2002 Jul;51(3):233-5.  4. The

antimicrobial efficacy

of

the

erbium,

chromium:

yttrium-scandium-gallium-garnet

laser

with

radial

emitting

tips

on root canal

dentin walls infected with Enterococcus faecalis: Wanda Gordon, DMD, Vahid A. Atabakhsh, DDS, Fernando Meza, DMD, Aaron

Doms, DDS, Roni Nissan, DMD, Ioana Rizoiu, MS and Roy H. Stevens, DDS, MS JADA 2007; 138(7): 992-1002.

Warning:

Patients Urged to Ask their Dentists

About the Risk of Cross Contamination!

Cross contamination is a huge threat

1,2,3,4

:

•

The CDC defines cross-contamination as the act

of spreading bacteria and viruses from one surface

to another. Blood-borne viruses have the ability to

live on objects and surfaces for as long as a week.

•

Sterilization techniques used for the dental burs

used with the high speed drill and endodontic files

used in root canals are not effective.  This is a

serious health threat for many people.

PAGE 14

NO Risk of Cross-Contamination:

WaterLase

MD™

reduced

E.

faecalis

2.86 times more effectively than NaOCl³

1. Dental Burs and Endodontic Files: Are Routine Sterilization Procedures Effective?: Archie Morrison, DDS, MS, FRCD(C); Susan Conrod, DDS JCDA •

www.cda-adc.ca/jcda •

February 2009, Vol. 75, No. 1.  2. Contaminated dental instruments:

Smith A, Dickson M, Aitken J, Bagg J.J Hosp Infect. 2002 Jul;51(3):233-5.  3. The antimicrobial efficacy of the erbium, chromium:yttrium-scandium-gallium-garnet laser with radial emitting tips on root canal dentin walls infected with

Enterococcus faecalis: Wanda Gordon, DMD, Vahid A. Atabakhsh, DDS, Fernando Meza, DMD, Aaron Doms, DDS, Roni Nissan, DMD, Ioana Rizoiu, MS and Roy H. Stevens, DDS, MS JADA 2007; 138(7): 992-1002

Burs and Endo Files:

•

15% of “sterilized”

burs and up to 76% of “sterilized”

endodontic files carry pathogenic micro-organisms.

•

Complex and rugged bur surface difficult to sterilize.

•

Autoclaving fails 15% of the time to decontaminate burs

WaterLase Tips:

•

Smooth tip surface does not harbor debris or bacteria

like abrasive surface of burs or files.

•

YSGG laser energy is bacteriacidal.

•

Single-use, disposable tips that work without the need to

contact tissue.  Also eliminates accidental sticks with

contaminated burs.

WaterLase Laser Technology Eliminates the Risk

of Cross Contamination and Contagion

PAGE 15

2

1,

3

1

Award winning IP:

Recognized for innovation, leadership, and the development of numerous disruptive technologies, most

notably the development of a new surgical system to cut human tissue in a biological and atraumatic way.

Received Astrum Award at MDB Capital’s 2011 Bright Lights Conference.

Strategy:

Currently

working

with

highly

regarded

IP

consulting

company

to

analyze

our

patent

families

and

determine

those with the greatest potential:

–

Dentistry (including new lasers for hard and soft tissue, a laser toothbrush, flavored water)

–

Ophthalmology (including procedures for presbyopia, glaucoma, maxillofacial surgery)

–

Orthopedics and pain management (including use as a general surgical knife)

Internal development, licensing, and legal action against infringers.

Intellectual Property

PAGE 16

•

•

•

•

Current

Status:

BIOLASE

currently

has

279

issued

and

pending

patents,

70%

of

which

are

related

to

our

core Er;Cr:YSGG technology and medical lasers.

Filing costs and maintenance

are

closely

monitored.

Funding

for

redundant

patents

and

patents

with a low-

probability for issuance are stopped.

Patent Portfolio

Issued

Pending

Total

U.S.

84

46

130

International

74

75

149

Total

158

122

279

PAGE 17

Current

Line

of

BIOLASE

Products

All-tissue

dental

lasers:

Our

all-tissue

lasers

include

our

new

flagship

laser,

the

revolutionary

WaterLase iPlus, and the WaterLase MD Turbo.

Diode

soft-tissue

dental

lasers:

Our

soft

tissue

lasers

include

the

ezLase

total

diode

solution,

which

offers

power

and

portability,

and

the

revolutionary

iLase,

a

portable

diode

laser

with

no

foot

pedal, power cord, or external controls.

Medical:

The

Diolase

10

offers

high

intensity

laser

therapy

in

the

palm

of

your

hand

for

pain

management.

Digital

Imaging:

We

offer

a

full

line

of

digital

imaging

equipment,

including

cone

beam

3-D

dental

imaging and CAD/CAM digital dental impressions.

PAGE 18

Patented laser toothbrush for Home Use

•

BIOLASE is currently developing a laser toothbrush for consumer home-use in connection with a license

agreement with The Proctor and Gamble Company (“P&G”).

•

Research indicates that a laser toothbrush for home-use will whiten teeth, disinfect teeth and gums, bio-

stimulate

teeth

and

gums,

relieve

pain,

and

perform

photodynamic

therapy.

•

No other product currently on the market can perform all of these functions.

New soft-tissue lasers

•

BIOLASE is also engineering a more powerful diode soft-tissue laser for launch in 2012 which will be the

first offer multiple wavelengths and power up to 40 watts.  

Further Opportunities to Expand in Dentistry

PAGE 19

With our patented WaterLase and diode technologies, we have created technological

platforms that have the ability to extend far outside of dentistry.  This expansion into new

markets is a fundamental effort within BIOLASE.  We expect to greatly expand our

addressable markets in the coming years which, we believe, has the potential to 

substantially increase our revenues.  Each of these potential markets represents a multi-

billion dollar opportunity.

Ophthalmology:

We

currently

hold

13

issued

and

20

pending

U.S.

and

International

patents

in

four

patent

families in the field of ophthalmology, giving us a wide range of applications and coverage.  Our patented   

technology has the capability to restore the elasticity of the eye and allow it to return to normal function,

eliminating presbyopia.  Management has established a new subsidiary, OCULASE, which will own and

develop BIOLASE’s ophthalmic assets and technologies.   In 2012, we expect approval to market for glaucoma

and dry eyes.  We expect approval to market WaterLase technology for presbyopia internationally in 2013 and

in the United States in 2014.

Further Opportunities to Expand in Medicine

PAGE 20

Pain

Management:

We

anticipate

launching

a

new

deep-tissue

hand

piece

and

upgraded

laser

for

pain therapy in 2012 which will coincide with a new marketing campaign.

Podiatry:

We

have

found

that

our

Diolase

10

technology

is

very

effective

in

the

treatment

of

nail

fungus

and

we

are completing the clinical and regulatory requirements necessary to enter the market in 2012.

Orthopedics:

We

are

working

with

several

key

manufacturers

and

universities

to

provide

solutions

that

are

not

currently available.  We are investigating opportunities for several orthopedic applications and anticipate filing

several 510(k) applications over the next 12 months.

Aesthetics:

We

have

various

FDA

approvals

for

applications

in

dermatology,

plastic

surgery,

and

oculoplastics and are currently investigating options for entering these markets in 2012.

PAGE 21

Further Opportunities to Expand in Medicine

(Continued)

How BIOLASE is positioned for a successful turnaround:

•

BIOLASE

has

a

better

organizational

structure,

better

cost

control,

and

more

efficient

&

effective   

•

Our

lower

cost

structure

and

growing

direct

sales

force

will

allow

us

to

leverage

our

earnings  

•

The

BIOLASE

brand

is

currently

known

by

over

80%

of

North

American

dentists

and

is

growing 

•

BIOLASE

has

the

largest

installed

base

of

dental

lasers

which

equates

to

recurring

revenues

from

•

BIOLASE

has

more

products

available

than

ever

before.

•

BIOLASE

has

more

clinical

trials,

more

FDA

approvals,

and

more

patents

and

pending

patents

than 

Foundation for a Successful Recovery

PAGE 22

management than ever before.

compared to BIOLASE of the past.

internationally.

consumables, warranties, and service contracts.

ever before.

How BIOLASE is Positioned in the Dental Market   

BIOLASE United States

BIOLASE International

Total: 12,500

Total: 5,500

Grand Total: 18,000

2,800

2,700

5,700

6,800

PAGE 23

Owning BIOLASE Means Owning the Hard

Tissue Dental Laser Market…

Biolase

80%

Source: Biolase Technology Licensing Reports

PAGE 24

…and the Overall Dental Laser Market.

45%

Source: iData Research Inc.

2009 US Dental Laser Market: Hard & Soft Tissue

PAGE 25

Biolase

Our Market Opportunity in Dentistry

BIOLASE’s global market opportunity is tremendous! 

•

176,000

dentists

in

the

US

and

Canada.

1

•

Over

1.2

million

dentists

in

134

countries.

2

•

18,000 systems in over 11,000 practices.

•

Every 1% of further market penetration is equal to an

opportunity of well over $600 million in revenues.

Estimated total global market of 1,200,000,

which is growing rapidly due to new markets

such as China, India, and Indonesia.

18,000

3

systems

sold

worldwide.

1. American Dental Association.  2. World Federation of Dentistry.  3. 1998-present over 17,300 BIOLASE systems sold.

PAGE 26

Our current market penetration is approximately

3% in the United States and slightly less than 1%

internationally! 

Substantial Opportunity in Emerging Markets

1. World Federation of Dentistry

Practicing Dentists

PAGE 27

Western Europe

240,000

dentists

1 dentist / 1,800

population

Eastern Europe

120,000

dentists

1 dentist / 4,000 population

China

16,000 dentists

1 dentist / 82,300 population

Japan

63,000 dentists

1 dentist / 2,000

population

Rest of Asia

43,000 dentists

1 dentist / 14,000

population

Middle East

19,000

dentists

1 dentist / 3,100 population

India

35,000

dentists

1 dentist / 33,900 population

Latin America

298,000

dentists

1 dentist / 5,600 population

North America

176,000 dentists

1 dentist / 1,900 population

Worldwide Total

1,200,000 dentists

1

Expected Growth of Emerging Markets

PAGE 28

Emerging Markets are expected to be bigger than Developed Markets by 2050.

1,2

•

Forecasts predict that the top 5

economies in 2050 will include China,

the United States, India, Japan, and

Germany.

1

•

Led by China, at >800%, and India, at

>600%, the rise in income per capita in

the emerging world from 2010 to 2050

will dwarf that of the United States, at

<100%.

1

•

Other projected high growth emerging

markets include Russia (575%),

Indonesia

(400%),

and

Brazil

(200%).

1

1. Source: HBC Calculations; 2. Chart in Trillions of Constant US 2000 Dollars.

BIOLASE Technology, Inc. Today

Company

Headquarters

in

Irvine,

California

PAGE 29

•

We have over 170 employees worldwide.

•

We have sales offices in the U.S., Floss (Germany),

Madrid (Spain), Shanghai (China), and Mumbai (India),

with expansion planned in Dubai (UAE), and Rio de

Janero (Brazil). We also have training facilities in

Charlotte, NC, St. Louis, MO, and Irvine, CA.

BIOLASE Europe in Floss, Germany

BIOLASE is the Global Leader in Dental Lasers:

•

Our 57,000 sq. ft. fcorporate HQ in Irvine houses

administrative,  sales,  marketing, customer care, training,

manufacturing, and  R&D. This facility can accommodate

growth to $250 million.

•

We also have manufacturing capabilities in Floss, Germany.

Operations

•

We are ISO 9001 certified and FDA GMP with clean room

operations.  We also have manufacturing capabilities in

Floss, Germany.

•

Nearly 100% of our components and subassemblies are

manufactured in our facility and/or the U.S.

PAGE 30

•

We have a highly skilled R&D team with

extensive medical device and laser

development expertise.   We are highly

focused in improving and extending  our

dental and medical product portfolio.

Manufacturing and Research & Development

0.5

1.0

Chart & Financial History

20

15

10

5

BLTI

SHARE

PRICE

1994-2006 Pignatelli

Chairman of the Board

Exclusive distribution partnership with

Henry Schein Aug 2006–Aug 2010

Aug 2010-Present

Pignatelli CEO &

Board Chairman

1998  FDA

Clearance

WaterLase

PAGE 31

Market Data (NASDAQ: BLTI)

PAGE 32

As of September 15, 2011:

Share price……………….....………………………...…………......................................................................

Shares issued and outstanding…………………………………………………………....….……………

Public float (shares held by others than the CEO and Board).……………………….....….………..…

Average daily volume (three month average)……………………………………..……………….……......

Market capitalization……………………………………………………………......…..………………..

Percentage of shares held by institutional holders (at June 30, 2011)..…….................…….

Short position……………………………………………………………………….………………………….

Dividend yield………………………………………………………………………………..…….….

30,300,000

28,900,000

590,000

$106,900,000

approximately

57%

6,952,000

4%

Annual

Stock

BIOLASE is currently covered by analysts from Needham & Company LLC, WJB Capital Group, and Rodman & Renshaw

LLC and is part of both the Russell Global and Russell 2000 Indexes. 

$3.53

Financial Highlights

PAGE 33

Turnaround:

For

the

nine

month

period

ended

June

30,

2011,

BIOLASE

generated

non-GAAP

net

income

of approximately $885,000, as compared to a non-GAAP net loss of approximately $9.3 million for the nine

month period ended June 30, 2010.

Insider Purchases:

During 2011, officers and directors have purchased approximately 109,700 shares of

stock in the open market for approximately $440,000.  In addition, officers and directors have converted

approximately 523,000 options into shares of common stock.

Employee

Stakeholders:

BIOLASE’s

entire

executive

team

holds

options

to

purchase

common

stock. 

As of June 30, 2011, essentially all of our employees held 3,000,000 options.

CEO

Stakeholder:

BIOLASE’s

Chairman,

President,

and

CEO,

Federico

Pignatelli,

has

an

annual

salary

of one dollar.  Mr. Pignatelli owns approximately 1.7 million shares of stock and 200,000 options to purchase

common stock.  The only way that Mr. Pignatelli will make money in 2011 is as a shareholder.

Recent Developments

Ophthalmology:

In September In June 2011, BIOLASE entered into an agreement with Daniel S. Durrie,

M.D.,

an

internationally

recognized

refractive

surgeon,

to

serve

as

BIOLASE’s

primary

ophthalmic

expert

resource and partner with management to oversee the development and execution of our clinical studies and

consult

on

ophthalmic

applications

for

our

intellectual

property

portfolio.  In September 2011, BIOLASE

established a new subsidiary, OCULASE, which will own and develop BIOLASE’s ophthalmic assets and

technologies.

We

expect

approval

to

market

for

glaucoma

and

dry

eyes

in

2012

and

approval

to

market

WaterLase technology for presbyopia internationally in 2013 and in the United States in 2014.

Asian

Offices:

In

June

2011,

BIOLASE

officially

opened

BIOLASE

Technology

Asia

Pacific,

its

Asian

headquarters,

in

Shanghai,

China,

and

a

direct

sales

and

service

office,

BIOLASE

India

Private

Limited,

in

Mumbai, India.

Digital

Imaging

Sales:

At

the

end

of

the

second

quarter,

BIOLASE

received

its

first

orders

for

its

state

of

the

art dental imaging devices for delivery in the third quarter.

PAGE 34

Recent Developments (continued)

Direct

Sales

in

Germany:

BIOLASE

has

regained

the

ability

to

sell

direct

or

through

other

distributors

from Henry Schein Inc. (NASDAQ: HSIC) for all of its international territories and has announced plans to

expand BIOLASE Europe, GMBH, to now include a direct sales force, along with service and support

operations, for the German market.

Additions

to

the

Management

Team:

BIOLASE

has

recently

hired

Richard

Whipp

as

Director

of

Operations

and Ehab Esmail as Vice President of Global Regulatory, Quality and Clinical Affairs.

Private

Placement:

In

June

2011,

BIOLASE

raised

$9

million

from

institutional

investors

in

a

private

placement

through

the

sale

of

1.6

million

shares

of

common

stock

and

812,000

warrants.

PAGE 35

BIOLASE Technology, Inc.

Federico Pignatelli, CEO

NASDAQ: BLTI

www.biolase.com

JMP Securities Healthcare Conference

September 27-28, 2011, New York